Page 4 of 4

CLAIMS AMENDMENTS

1. (Cancelled)

2. (Currently Amended) MethodUse according to claim 5 ± 1 , wherein the pharmacological agent is a part of a preparation which is intended for administration administered by means of intravenous injection.

3. (Currently Amended) <u>MethodUse</u> according to claim <u>5</u> 1, wherein the pharmacological agent is a part of a preparation which is intended for administration administered by means of a nasal spray.

4. (Cancelled)

5. (New)

Method of diagnosing an obsessive compulsive disorder comprising the steps of:
administering to a patient a pharmacological agent comprising at least one substance
within the group GnRH analogues that release gonadotropins from the pituitary.

6. (New)

Method of assessing the severity of an obsessive disorder comprising the steps of: administering to a patient with obsessive compulsive disorder a pharmacological agent comprising at least one substance within the group GnRH analogues that release gonadotropins from the pituitary.

7. (New)

Method according to claim 6, wherein the pharmacological agent is administered by means of intravenous injection.

8. (New)

Method according to claim 6, wherein the pharmacological agent is administered by means of a nasal spray.

Page 5 of 5

9. (New)

The method of claim 5 comprising the additional steps of:

collecting at least one blood sample from the patient within a short time interval after the administration of the pharmacological agent,

determining the concentration of LH and/or FSH of the at least blood sample collected after the administration of the pharmacological agent,

comparing the concentration of LH and/or FSH of the at least one blood sample collected after the administration of the pharmacological agent to a blood concentration of LH and/or FSH before the administration of the pharmacological agent.

10. (New)

The method of claim 9 wherein the pharmacological agent is administered via an injection.

11. (New)

The method of claim 9 wherein the pharmacological agent is administered via a nasal spray.

12. (New)

The method of claim 9 comprising the additional steps of:

collecting at least one blood sample from the patient before the administration of the pharmacological agent, and

determining the concentration of LH and/or FSH of the blood sample collected before the adminstration of the pharmacological agent.

13. (New)

The method of claim 12 wherein the pharmacological agent is administered via an injection.

14. (New)

The method of claim 12 wherein the pharmacological agent is administered via a nasal spray.

Page 6 of 6

15. (New)

The method of claim 6, comprising the additional steps of:

collecting at least one blood sample from the patient within a short time interval after the administration of the pharmacological agent,

determining the concentration of LH and/or FSH of the at least one blood sample collected after the administration of the pharmacological agent,

comparing the concentration of LH and/or FSH of the at least one blood sample collected after administration of the pharmacological agent to a blood concentration of LH and/or FSH before the administration of the pharmacological agent,

determining the severity of the obsessive compulsive disorder using the blood concentration of LH and/or FSH of the at least one sample collected after the administration of the pharmacological agent.

16. (New)

The method of claim 15 wherein the pharmacological agent is administered via an injection.

17. (New)

The method of claim 15 wherein the pharmacological agent is administered via a nasal spray.

18. (New)

The method of claim 15 comprising the additional steps of:

collecting at least one blood sample before the administration of the pharmacological agent, and

determining the concentration of LH and/or FSH of the blood sample collected before the administration of the pharmacological agent.

19. (New)

The method of claim 18 wherein the pharmacological agent is administered via an injection.

Page 7 of 7

20. (New)

The method of claim 18 wherein the pharmacological agent is administered via a nasal spray.

21. (New)

The method of claim 9 wherein the time interval is less than 90 minutes.

22. (New)

The method of claim 9 comprising the additional step of: analyzing the blood samples with a radioimmunologic technique.